title: Is seroquel developing an illicit reputation for misuse/abuse?
abstract: Quetiapine, an atypical antipsychotic, has been the subject of a series of case reports that suggest a potential for misuse/abuse. The available cases indicate a male predominance; oral, intranasal, or intravenous routes of administration; misuse/abuse in jail or inpatient psychiatric settings; and subjects with extensive histories of polysubstance abuse. While possible pharmacological explanations have been proffered, compared to the other atypical antipsychotics, there is no clear explanation for an alleged higher risk of misuse/abuse with quetiapine. Likewise, there are no available animal or human empirical studies to evaluate risk. At this juncture, clinicians in psychiatric and primary care settings can only remain alert to a potential risk, particularly in patients who meet the current demographic profile.
authors.affiliation: Dr. R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine in Dayton, Ohio, and Director of Psychiatry Education at Kettering Medical Center in Kettering, Ohio.
authors.forename: Randy A
authors.initials: RA
authors.lastname: Sansone
authors.forename: Lori A
authors.initials: LA
authors.lastname: Sansone
references.citation: Am J Health Syst Pharm. 2007 Apr 1;64(7):723-5
references.pmid: 17384357
references.citation: Hum Psychopharmacol. 2008 Jul;23(5):417-24
references.pmid: 18425995
references.citation: J Clin Psychiatry. 2005 Oct;66(10):1285-8
references.pmid: 16259542
references.citation: Expert Opin Drug Saf. 2008 Nov;7(6):739-48
references.pmid: 18983220
references.citation: Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):3-7
references.pmid: 16001094
references.citation: Am J Psychiatry. 2005 Sep;162(9):1755-6
references.pmid: 16135642
references.citation: J Clin Psychopharmacol. 2008 Apr;28(2):221-4
references.pmid: 18344735
references.citation: J Clin Psychiatry. 2008 Jan;69(1):162-3
references.pmid: 18312052
references.citation: Am J Psychiatry. 2007 Jan;164(1):173-4
references.pmid: 17202567
references.citation: J Psychiatr Pract. 2006 Nov;12(6):348-63
references.pmid: 17122696
references.citation: South Med J. 2007 Aug;100(8):834-6
references.pmid: 17713313
references.citation: CNS Drugs. 2006;20(5):389-409
references.pmid: 16696579
references.citation: Am J Psychiatry. 2007 Feb;164(2):350
references.pmid: 17267808
references.citation: Am J Psychiatry. 2004 Sep;161(9):1718
references.pmid: 15337673
references.citation: J Clin Psychopharmacol. 2004 Oct;24(5):532-5
references.pmid: 15349010
references.citation: Am J Health Syst Pharm. 2008 Apr 1;65(7):611-8
references.pmid: 18359967
references.citation: Am J Psychiatry. 2008 Jul;165(7):918
references.pmid: 18593794
references.citation: CMAJ. 2005 Jun 21;172(13):1703-11
references.pmid: 15967975
references.citation: J Psychiatry Neurosci. 2004 Nov;29(6):452-7
references.pmid: 15644986
references.citation: Can J Psychiatry. 2004 Oct;49(10):711
references.pmid: 15560324
references.citation: Am J Psychiatry. 2007 Jan;164(1):174-5
references.pmid: 17202569
references.citation: J Psychopharmacol. 2007 Jun;21(4):392-9
references.pmid: 17656426
references.citation: Perspect Psychiatr Care. 2008 Jul;44(3):202-6
references.pmid: 18577126
references.citation: Am J Addict. 2008 Sep-Oct;17(5):454-5
references.pmid: 18770092
references.citation: S D Med. 2007 Nov;60(11):437, 439-41, 443 passim
references.pmid: 18196687